Biologic Development
Biologic drugs including monoclonal, bispecific, and
fragment-based antibodies are produced from living host cells and are engineered to
target cells involved in cancer, autoimmune disorders, and infectious diseases among
others.
The therapeutic antibody development process can be
broken into two main workflows—Molecule Development and Cell Line Development. This
interactive infographic takes a closer look at these two workflows focusing on
Sartorius
instruments, solutions, and services available to drive
successful
therapeutic discovery and production.
01
Molecule Development
Molecule Development focuses on the initial
identification, characterization, and optimization of antibodies or antibody
derivatives. Various techniques are used to identify the molecular target and
screen large libraries to select the most promising hits. These leads are then
refined to improve therapeutic properties like affinity, specificity, and
efficacy.
02
Cell Line Development
Cell Line Development aims to establish a stable and
productive cell line that can reliably produce the optimized antibody. The best
performing cell line is subsequently optimized and used to establish the cell
bank which serves as the main production engine for therapeutic
manufacturing.